Conference - San Diego, CA, United States
The newest therapies in more than a decade for people infected with the Hepatitis C virus (HCV) have recently hit the market. Hear about the chemistry of this new class of protease inhibitors and progress on 2nd generation versions, as well as updates on the clinical progress and chemical optimizations of other direct acting antivirals (DAAs). An emphasis will be on progress of various combinations of the new DAAs, especially in the context of an ideal interferon-free regimen. Newer anti-HCV drug candidates, including those that target host/virus interactions will also be covered.
Sponsoring Institution: Cambridge Healthtech Institute
April 18 - 19, 2012 (08:00 AM – 07:00 PM)
San Diego, CA
www.drugdiscoverychemistry.com/hcv
Contact: Nilufer Donmez (ndonmez@healthtech.com)
Phone: 781-247-6257
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
